secwatch.observer — SEC 8-K summary
======================================

Issuer:     Candel Therapeutics, Inc. (CADL)
CIK:        0001841387
Form:       8-K
Filed at:   2025-10-14T23:59:59+00:00
Accession:  0001193125-25-238254
Event type: other_material
Sentiment:  positive
Materiality: 0.85
Item codes: 1.01, 2.02, 2.03, 3.02, 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Candel Therapeutics secures $130M loan; reports positive CAN-3110 survival data
-------------------------------------------------------------------------------

- Entered $130M term loan facility with Trinity Capital; $50M drawn at closing, up to $80M additional subject to milestones.
- Cash and cash equivalents $87.2M as of Sept 30, 2025; loan carries 10.25% initial rate, 36-month interest-only period.
- Phase 1b CAN-3110 interim data: median OS 11.8 months (arm A) and 12.0 months (arm B); two patients alive >40 months post-single injection.
- Strategic pivot: seek external partnerships for CAN-2409 in PDAC; focus capital on early localized prostate cancer and NSCLC.
- Proceeds to initiate phase 3 CAN-2409 trial in NSCLC in Q2 2026 and support BLA submission for prostate cancer planned Q4 2026.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1841387/000119312525238254/0001193125-25-238254-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1841387/000119312525238254/cadl-20251014.htm
  HTML page:      https://secwatch.observer/filing/0001193125-25-238254

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer